Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases

WJ Sandborn, S Hanauer, G Van Assche… - Journal of Crohn's …, 2014‏ - academic.oup.com
Background and aims Treatment goals in inflammatory bowel diseases are evolving beyond
the control of symptoms towards the tight control of objectively-measured gastrointestinal …

Optimising monitoring in the management of Crohn's disease: a physician's perspective

P Papay, A Ignjatovic, K Karmiris… - Journal of Crohn's …, 2013‏ - academic.oup.com
Management of Crohn's disease has traditionally placed high value on subjective symptom
assessment; however, it is increasingly appreciated that patient symptoms and objective …

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial

P Rutgeerts, G Van Assche, WJ Sandborn, DC Wolf… - Gastroenterology, 2012‏ - Elsevier
BACKGROUND & AIMS: We investigated the efficacy of adalimumab for inducing and
maintaining mucosal healing in patients with Crohn's disease (CD). METHODS: A …

Implementing changes in clinical practice to improve the management of Crohn's disease

R Panaccione, T Hibi, L Peyrin-Biroulet… - Journal of Crohn's and …, 2012‏ - Elsevier
The introduction of anti-tumour necrosis factor therapies has provided highly effective
treatments for Crohn's disease, making it possible to significantly improve the prognosis of …

Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn's disease: predictors of efficacy in clinical practice

A Echarri, V Ollero, M Barreiro-de Acosta… - European Journal of …, 2015‏ - journals.lww.com
Materials and methods A prospective analysis was carried out of 68 antitumor necrosis
factor-naive Crohn's disease patients treated with adalimumab for 2 years. Clinical and …

Evaluation of “top-down” treatment of early Crohn's disease by double balloon enteroscopy

R Fan, J Zhong, ZT Wang, SY Li… - World Journal of …, 2014‏ - pmc.ncbi.nlm.nih.gov
AIM: To assess “top-down” treatment for deep remission of early moderate to severe Crohn's
disease (CD) by double balloon enteroscopy. METHODS: Patients with early active …

The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy

S Travis, BG Feagan, P Rutgeerts… - Journal of Crohn's …, 2012‏ - academic.oup.com
Anti-tumour necrosis factor antagonists have appreciably improved patient outcomes in
Crohn's disease, shifting the goals of treatment from control of symptoms to clinical …

AbbVie en gastroenterología

O Seco, EM Continua‏ - abbviepro.com
Nuestro compromiso y apuesta por la gastroenterología se refleja en nuestros más de 10
años de experiencia en esta área. Continuamos trabajando e investigando para encontrar …

Adalimumab in der Behandlung des adulten Morbus Crohn–Update eines Konsensus der Arbeitsgruppe Chronisch Entzündliche Darmerkrankungen der …

G Novacek, T Haas, P Knoflach… - Zeitschrift für …, 2013‏ - thieme-connect.com
TNF-alpha-Antikörper haben den Verlauf von Morbus Crohn mit moderatem bis schwerem
Verlauf wesentlich verbessert. Adalimumab ist der erste vollständig humane, monoklonale …

[PDF][PDF] Ocena wpływu leczenia przeciwciałami anty-TNF-alfa na ekspresję wybranych receptorów oraz białek biorących udział w procesie apoptozy nabłonka i …

LP Eder‏ - wbc.poznan.pl
Jeszcze do połowy XX wieku uważano, że jedynym procesem prowadzącym do śmierci
komórek jest martwica (nekroza). W latach 60-tych zaczęto jednak opisywać zjawisko, które …